InxMed (Shanghai) Co., Ltd.
InxMed (Shanghai) Co., Ltd.
Explore linked clinical trials.10 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors | Solid Tumor | Active, not recruiting | Phase 1 / Phase 2 | 2026-07-17 | NCT05379946 | |
| a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors | Solid Tumor | Active, not recruiting | Phase 1 / Phase 2 | 2026-07-02 | NCT06166836 | |
| FAK Inhibitor in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Not yet recruiting | Phase 1 | 2026-05-19 | NCT07596381 | |
| IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer | Platinum-resistant Ovarian Cancer | Recruiting | Phase 1 / Phase 2 | 2026-05-04 | NCT05551507 | |
| A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-03-03 | NCT07174908 | |
| IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors | PDAC; Solid Tumor Cancer | Recruiting | Phase 1 / Phase 2 | 2026-02-27 | NCT07441174 | |
| IN10018 Combination Therapy in Treatment-naïve ES-SCLC | Small Cell Lung Cancer Extensive Stage | Recruiting | Phase 1 / Phase 2 | 2025-04-30 | NCT06030258 | |
| IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer | Ovarian Cancer Recurrent | Recruiting | Phase 2 | 2025-04-30 | NCT06014528 | |
| IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC | non-small cell lung carcinoma | Recruiting | Phase 1 / Phase 2 | 2025-04-30 | NCT05994131 | |
| IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-04-30 | NCT05827796 |